Drug Type Monoclonal antibody |
Synonyms PT 240, PT240 |
Target |
Mechanism CD47 modulators(Cluster of differentiation 47 modulators), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), T lymphocytes stimulants |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization Phanes Therapeutics, Inc.Startup |
Active Organization- |
Inactive Organization Phanes Therapeutics, Inc.Startup |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hematologic Neoplasms | Preclinical | US | Phanes Therapeutics, Inc.Startup | - |
Solid tumor | Preclinical | US | Phanes Therapeutics, Inc.Startup | - |